Cenna Biosciences Inc.

11:00 AM - 11:15 AM, Tuesday, June 4,2019 ・ Theater 2
CENNA Biosciences is a privately-held biopharmaceutical company focused on the discovery and development of novel drugs for the prevention and treatment of Alzheimer’s disease (AD). CENNA has a novel patented technology that arrests the underlying cause of the disease, the deposition of the toxic species, Aß. CENNA is developing several peptide and small molecule drug candidates with the ability to inhibit Aß in vitro, in a transgenic mouse model of AD in AD patient-derived induced stem cells, without targeting, modifying or inhibiting either ß- or -secretase activities. CENNA’s technology is the earliest for intervention and it addresses previous failures by others. It is anticipated that CENNA’s therapeutics will have a significant impact in both treatment and prevention modes and be useful throughout the course of disease. Preclinical studies are in progress with IND filing for the first candidate in 2019. CENNA’s exit strategy is to be acquired after the completion of Phase II
Cenna Biosciences Inc.